OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Interactive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • In-person and virtual events just for HCPs
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe
Advertisement
Advanced Endometrial Cancer: Treatment Optimization : Episode 8

Video

December 13, 2022

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

Author(s):

Courtney R. Arn, APRN-CNP,Kimberly Halla, NP

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

EP: 1.Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

EP: 2.Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

EP: 3.Currently Available Treatment Modalities in Endometrial Cancer

EP: 4.First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

EP: 5.Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

EP: 6.Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

EP: 7.Treatment Options for Patients with Recurrent Endometrial Cancer

Now Viewing

EP: 8.Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

EP: 9.Monitoring Patients on Therapy for Recurrent Endometrial Cancer

EP: 10.Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

EP: 11.Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

EP: 12.Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

EP: 13.Greatest Unmet Needs for Patients with Endometrial Cancer

EP: 14.Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Related Videos
Kathleen N. Moore, MD, MS
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Related Content
Advertisement
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute
November 5th 2024

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Related Content
Advertisement
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute
November 5th 2024

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact